Estrogen News and Research

Latest Estrogen News and Research

BREVAGen test offers precise breast cancer risk assessment

Perlegen Sciences, which develops genetic tests that correlate genetic variation to disease risk and drug response, announced today that its BREVAGen™ breast cancer risk stratification test is now clinically available in select U.S. markets. Perlegen plans to add sales areas to make the test available nationwide over the next few months.

24 Sep 2009

Oncotype DX Recurrence Score provides consistent results across varied patient populations

Genomic Health, Inc. today, announced results from the first study to compare the distribution of Oncotype DX® Recurrence Score® results between European, Middle Eastern and United States patient populations.

22 Sep 2009

Gene variant shows a strong gender bias for cancer predisposition

Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.

22 Sep 2009

Swedish researcher to receive Fernström Foundation's Nordic Prize

Internationally renowned Swedish researcher Professor Jan-Åke Gustafsson, from KI and the University of Houston, is this year's recipient of the Fernström Foundation's Nordic Prize. The prize, which is worth SEK 1 million, is one of Scandinavia's most prestigious medical prizes.

21 Sep 2009

Postmenopausal women benefit as much from exercise as younger women

In two papers based on the experiments and published in recent months, UC Berkeley researchers report that postmenopausal women can achieve the same health benefits from regular, vigorous exercise as younger women do.

21 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

BioSante and Cell Genesys encourage stockholders to vote shares

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.

18 Sep 2009

African Americans at higher risk of developing potentially deadly DVT and PE than other ethnic populations

Speaking at the Venous Disease Coalition (VDC) Annual Meeting today, Dr. Garth Graham from the Office of Minority Health at the Department of Health and Human Services followed up on last year's Surgeon General's Call to Action by focusing attention on the African American population which is at significantly increased risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

18 Sep 2009

Breast cancer prevention drugs may negatively affect patients

Three drugs, including tamoxifen, reduce a woman's chance of getting breast cancer, but each drug carries distinct potential harms of its own, according to a new report from HHS' Agency for Healthcare Research and Quality.

16 Sep 2009

Phthalates & Parabens Profile helps identify exposure levels to chemicals

Personal care products that we use everyday contain chemicals that act as endocrine disruptors, which hinder the normal functions of our hormone systems. Phthalates, also known as plasticizers, are added to plastics to make them flexible to mold into shapes for product packaging and as fragrance for perfumes and air fresheners. Parabens are added to personal care products, such as cosmetics, to extend shelf-life and eliminate fungi and bacteria.

16 Sep 2009

Phase 3 clinical study results of bazedoxifene released

Wyeth Pharmaceuticals, a division of Wyeth, announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis.

15 Sep 2009

GTx to continue its toremifene Phase III high grade PIN clinical trial for prevention of prostate cancer

GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.

14 Sep 2009

Bioidentical hormone therapy is safe and effective for menopausal women

Life Extension(R), the company that long ago sounded the alarm on the dangers of synthetic hormone replacement therapy for menopausal women, has published still more proof that bioidentical hormones offer a far safer treatment option.

11 Sep 2009

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009

Gabapentin improves sleep quality in menopausal women

Gabapentin, a drug initially used to treat seizures, improves sleep quality in menopausal women with hot flashes, University of Rochester Medical Center researchers report online and in the September issue of the Journal of Women's Health.

9 Sep 2009

Obesity, alcohol and smoking linked to second breast cancer occurrence

It is well known that survivors of breast cancer have a much higher risk of developing a second breast cancer than women in the general population have of developing a first breast cancer. However, little is known about what lifestyle factors may make survivors more vulnerable to a second cancer.

9 Sep 2009

Researchers study tumor diversity to improve breast cancer treatment

One person's breast cancer is not the same as another person's, because the gene mutations differ in each tumor. That makes it difficult to match the best therapy with the individual patient.

5 Sep 2009

Oncotype DX multigene expression test for breast cancer patients

In an effort to provide breast cancer patients with prompt, critical information about treatment options for use at their first visit with the medical oncologist, a number of leading U.S. surgeons request Genomic Health's Oncotype DX molecular test at the time of surgery or biopsy.

4 Sep 2009

Biosante and Cell Genesys to merge after stockholders' approval

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies. On June 29, 2009, BioSante and Cell Genesys entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company.

3 Sep 2009

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. (NASDAQ:CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies.

3 Sep 2009